Watching Soligenix; Zacks Small-Cap Research Gives Stock $32 Price Valuation; Says "Model Is Highly Dependent Upon Continued Clinical Success Of The Company's Pipeline And Will Be Adjusted Accordingly Based Upon Future Clinical Results"
Watching Soligenix; Zacks Small-Cap Research Gives Stock $32 Price Valuation; Says "Model Is Highly Dependent Upon Continued Clinical Success Of The Company's Pipeline And Will Be Adjusted Accordingly Based Upon Future Clinical Results"
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.